A recent study published in the medical journal Gut has revealed a novel cancer-promoting mechanism of Streptococcus anginosus (Sa). The research shows that methionine metabolites produced by this bacterium can significantly contribute to the development of gastric cancer.

This finding deepens the understanding of the gut microbiome’s role in cancer and opens new paths for microbiota-targeted prevention strategies.

Understanding why cancer cells rely on specific genes is critical for designing effective targeted therapies.

 In this system, Fc could convert overexpressed H₂O₂ to produce ·OH. Importantly, Cur could form dynamic boronate ester bonds with BA, and be encapsulated in SPSAs-1 through responsive chemical bond to form SPSAs-2. The acidic microenvironment and excessive H₂O₂ within tumor cells cause the dissociation of boronate ester bonds and β-CD/Fc complexes, releasing Cur. As a result, the GSH level could be reduced through the combination of the BA-induced GSH consumption and Cur-induced inhibition of TrxR activation, further enhancing CDT efficacy.

Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have identified novel mechanisms by which a metabolic derivative of vitamin A—all-trans retinoic acid—compromises both the body’s normal anti-cancer immune response and, in a different context, the efficacy of a promising type of cancer vaccine.

Scientists at St. Jude Children’s Research Hospital found that tumor cells use LINE-1 retrotransposons to restructure the genome to promote cancer gene expression.

Removing part or all of the breast during breast cancer treatment is a potential outcome for some people. Reconstructive surgical procedures often involve prosthetic implants or transplanted tissue from elsewhere in the body. So, researchers reporting in ACS Applied Bio Materials developed a prototype injectable paste derived from human skin cells that could help restore breast volume after tumor removal, with less scarring and shorter healing time than current options.

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer. The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.

In the current study, published today in the journal Nature Biotechnology, Cheng and his colleagues created an exosome system that co-displays two therapeutic proteins to treat lung metastases. One protein blocks the PD-1/PD-L1 immune checkpoint pathway, a process that has been shown to boost the immune response against melanoma cells and shrink tumors. The other protein blocks the Wnt/β-catenin signaling pathway that drives immune exclusion in tumors, a phenomenon where immune cells are unable to infiltrate tumor tissues.